Статья: Возможности метаболической терапии у пациентов с пароксизмальной формой фибрилляции предсердий в сочетании с ожирением, артериальной гипертензией и/или ишемической болезнью сердца (2024)

1. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC // Europ Heart J. 2021. Vol. 42, N. 5. P. 373–498. doi: 10.1093/eurheartj/ehaa945
2. Trohman R.G., Huang H.D., Sharma P.S. Atrial fibrillation: primaryprevention, secondary prevention, and prevention of thromboembolic complications: part 1 // Front Cardiovasc Med. 2023. Vol. 10. P. 1060030. doi: 10.3389/fcvm.2023.1060030
3. Vizzardi E., Curnis A., Latini M.G., et al. Risk factors for atrial fibrillation recurrence: a literature review // J Cardiovasc Med (Hagerstown). 2014. Vol. 15, N. 3. P. 235–253. doi: 10.2459/jcm.0b013e328358554b
4. DiNicolantonio J.J., Lavie C.J., Fares H., et al. L-carnitine in the secondary prevention o fcardiovascular disease: systematic review and meta-analysis // Mayo Clin Proc. 2013. Vol. 88, N. 6. P. 544–551. doi: 10.1016/j.mayocp.2013.02.007
5. Zhao G., Zhang H., Wang Y., et al. Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure // Hellenic J Cardiol. 2020. Vol. 61, N. 2. P. 99–102. doi: 10.1016/j.hjc.2018.08.006
6. Kinugasa Y., Sota T., Ishiga N., et al. L-carnitine supplementation in heart failure patients with preserved ejection fraction; a pilot study // Geriatr Gerontol Int. 2020. Vol. 20, N. 12. P. 1244–1245. doi: 10.1111/ggi.14060
7. Dastan F., Talasaz A.H., Mojtahedzadeh M., et al. Randomized trial of carnitine for the prevention of perioperative atrial fibrillation // Semin Thorac Cardiovasc Surg. 2018. Vol. 30. P. 7–13. doi: 10.1053/j.semtcvs.2017.08.006
8. Shingu Y., Katoh N., Ooka T., et al. L-carnitine supplementation for the prevention of postoperative atrial fibrillation in aortic valve surgery // Gen Thorac Cardiovasc Surg. 2021. Vol. 69, N. 11. P. 1460–1466. doi: 10.1007/s11748-021-01616-2
9. Асташкин Е.И., Глезер М.Г. Липотоксические эффекты в сердце, наблюдаемые при ожирении // Артериальная гипертензия. 2009. Т. 15, № 3. С. 335–341. doi: 10.18705/1607-419X-2009-15-3-335-341
10. Zhang Y., Fu Y., Jiang T., et al. Enhancing fatty acids oxidation via L-carnitine attenuates obesity-related atrial fibrillation and structural remodeling by activating AMPK signaling and alleviating cardiac lipotoxicity // Front Pharmacol. 2021. Vol. 12. P. 771940. doi: 10.3389/fphar.2021.771940
11. Muszyński P., Bonda T.A. Mitochondrial dysfunction in atrial fibrillation-mechanisms and pharmacological interventions // J Clin Med. 2021. Vol. 10, N. 11. P. 2385. doi: 10.3390/jcm10112385
12. Gasparova I., Kubatka P., Opatrilova R., et al. Perspectives and challenges of antioxidant therapy for atrial fibrillation // Naunyn Schmiedebergs Arch Pharmacol. 2017. Vol. 390, N. 1. P. 1–14. doi: 10.1007/s00210-016-1320-9
13. Sciatti E., Lombardi C., Ravera A., et al. Nutritional deficiency in patients with heart failure // Nutrients. 2016. Vol. 8, N. 7. H. 442. doi: 10.3390/nu8070442
14. Song X., Qu H., Yang Z., et al. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials // Biomed Res Int. 2017. Vol. 2017. P. 6274854. doi: 10.1155/2017/6274854
15. Трухан Д.И. Роль и место L-карнитина в цитопротекции и коррекции метаболических процессов у пациентов с метаболическим синдромом // Мед. совет. 2017. Т. 12. С. 182– 7.EDN: ZQTJYB doi: 10.21518/2079-701X-2017-12-182-187